AbbVie Inc. (ABBV)
Overview · Option chain · Volatility · Expected-move history · Earnings
Cboe delayed options data · as of 00:33 UTC · Figures derived from the full chain (1,276 contracts, 15 expirations) · IV own-history percentile appears after 60 recorded days (3 so far)
Expected move — Sep 18, 2026 (16 days)
Methodology →Read from option prices: the at-the-money straddle costs this much, so the market is pricing a move of about that size in either direction by this date. It is an estimate of movement, not a prediction of direction.
Options are pricing a move of about ±4.1% (range 249.00–270.15) by Sep 18, 2026. ATM straddle: 10.57 @ strike 260 · ATM IV: 24.2%.
Probability distribution
Model & assumptions →The curve shows where a lognormal model, fed with current implied volatility, puts the range of outcomes at this expiration. Shaded: the expected-move band.
| Level | vs price | P(above)Model-estimated chance the stock finishes above a level at expiration, derived from current IV under a lognormal model with stated assumptions — an estimate, not a prediction. | P(below) |
|---|---|---|---|
| 233.62 | -10% | 98.0% | 2.0% |
| 246.60 | -5% | 83.8% | 16.2% |
| 259.58 | +0% | 49.0% | 51.0% |
| 272.56 | +5% | 16.2% | 83.8% |
| 285.54 | +10% | 2.8% | 97.2% |
Model-estimated probabilities of finishing above/below each level at expiration — estimates under stated assumptions, not predictions.
Probability explorer
Drag the slider to any level and see the model-estimated chance the stock finishes above or below it at the selected expiration.
Horizon: Sep 18, 2026 · lognormal model, zero drift — an estimate, not a prediction. Assumptions
Expirations
Open the chain →| Expires | DTEDays to expiration, in calendar days. | Implied move | ATM IV | Open int. |
|---|---|---|---|---|
| Sep 04, 2026 | 2 | ±1.6% | 26.3% | 10.5K |
| Sep 11, 2026 | 9 | ±3.0% | 24.0% | 2,361 |
| Sep 18, 2026 | 16 | ±4.1% | 24.2% | 56.4K |
| Sep 25, 2026 | 23 | ±4.8% | 23.9% | 1,161 |
| Oct 02, 2026 | 30 | ±5.5% | 24.1% | 1,173 |
| Oct 09, 2026 | 37 | ±6.2% | 24.2% | 130 |
| Oct 16, 2026 | 44 | ±7.2% | 25.2% | 25.6K |
| Nov 20, 2026 | 79 | ±10.5% | 28.2% | 27.2K |
| Dec 18, 2026 | 107 | ±12.0% | 27.8% | 36.0K |
| Jan 15, 2027 | 135 | ±13.4% | 27.3% | 53.8K |
| Feb 19, 2027 | 170 | ±15.4% | 28.6% | 7,291 |
| Mar 19, 2027 | 198 | ±16.6% | 28.5% | 11.2K |
Open interest by strike — Sep 18
Where option positions are concentrated. Teal bars are calls, red bars are puts; the dashed line is the current price.
Largest open-interest concentrations (all expirations ≤ 60 days): 280 C · 15.5K270 C · 11.8K260 C · 6,051290 C · 5,281250 C · 4,714
IV term structure
Volatility page →At-the-money implied volatility for each expiration. A hump around a date often marks a scheduled event the market is pricing.
When does open interest expire?
Implied vs realized volatility
HV from our stored daily closes (annualized); IV30 interpolated from the chain. Method
Price, last 60 sessions
Track record
Full history →Every trading day we record what the options market is pricing for each expiration — before the outcome is known. Once expirations start resolving, this section compares expected versus actual, and the record is never rewritten. Recording since Aug 31, 2026.
Past earnings reactions
Avg |reaction| 5.1% · median 5.1% (20 reports) — two-session close-to-close window; definition
About AbbVie Inc.
AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines. Its extensive therapeutic portfolio encompasses several key areas: Immunology and Inflammation: Leading products include HUMIRA, an injectable therapy for autoimmune and intestinal Behçet's diseases; SKYRIZI, which addresses moderate to severe plaque psoriasis in adults; and RINVOQ, a JAK inhibitor for moderate to severe active rheumatoid arthritis in adult patients. Oncology and Hematology: For blood cancers, AbbVie provides IMBRUVICA and VENCLEXTA (a BCL-2 inhibitor), both indicated for adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Virology: MAVYRET offers a treatment option for individuals with chronic HCV genotype 1-6 infection. Gastroenterology and Endocrinology: The company supplies CREON, an enzyme replacement therapy for exocrine pancreatic insufficiency, and Synthroid, used to manage hypothyroidism. Linzess/Constella helps treat irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation. Women's Health and Urology: Lupron serves as a palliative treatm
Healthcare · Drug Manufacturers - General · NYSE · Profile: Financial Modeling Prep
Related securities — Healthcare
PFE · IV 21.8%MRNA · IV 77.0%HIMS · IV 67.0%UNH · IV 27.3%LLY · IV 33.0%JNJ · IV 23.2%